Israel's MediWound Q1 revenue misses analyst expectations

[출처/시간] Reuters - 7:08 AM ET, 05/27/2026

Overview

* Israel biotechnology firm's Q1 revenue declined and ?missed analyst expectations
* Company reaffirmed full-year ?2026 revenue guidance of $24-26 mln
* Q1 revenue ?decline driven by BARDA timing and postponed shipments due to regional conflict

Outlook

* MediWound reaffirms 2026 full-year revenue guidance at $24-26 mln
* Company expects EscharEx Phase III trial enrollment completion by end of Q1 2027
* Initial NexoBrid BARDA procurement activity expected to begin in H2 2026

Result Drivers

* BARDA REVENUE TIMING - Co said Q1 revenue decline was primarily due ?to timing of BARDA-related revenues
* POSTPONED SHIPMENTS - Co cited ?postponed ?shipments related to regional conflict as a factor in ?lower Q1 revenue
* HIGHER R&D SPENDING - Research and development expenses increased due to costs associated with the EscharEx VALUE Phase ?III trial

Company ?press release:

Key Details



Metric Beat/Mis Actual Consensu
s s
Estimate


Q1 Miss $1.5 mln $3.12
Revenue mln (6
Analysts
)
Q1 EPS -$0.23
Q1 Net -$3 mln
Income
Q1 Beat -$7 ?mln -$7.81
Adjusted mln (2
EBITDA Analysts
)
Q1 Gross $323,000
Profit
Q1 -$8 mln
Operatin
g Income

Analyst Coverage

* The current average analyst ?rating on the shares is "buy" and the breakdown of ?recommendations ?is 6 "strong buy" or "buy", no "hold" and ?no "sell" or "strong sell"
* Wall Street's median 12-month price ?target for
Mediwound Ltd
is $31.50, about 88.8% above its May 26 closing price of $16.68

For questions concerning the data ?in this report, contact ?Estimates.Support@lseg.com. For any other ?questions or feedback, contact .

(This story was created using Reuters automation and ?AI based on LSEG and company data. It was checked and edited by ?a Reuters journalist ?prior to publication.)